Scarica l'app Stockscreener
24.16
2.24%
0.53
Dopo l'orario di chiusura:
24.16
Precedente Chiudi:
$23.63
Aprire:
$23.83
Volume 24 ore:
801.44K
Relative Volume:
1.35
Capitalizzazione di mercato:
$870.20M
Reddito:
$13.00M
Utile/perdita netta:
$-68.87M
Rapporto P/E:
-10.85
EPS:
-2.2276
Flusso di cassa netto:
$-76.68M
1 W Prestazione:
-5.55%
1M Prestazione:
+1.85%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$23.51
$24.90
Intervallo di 1 settimana:
$23.10
$25.52
Portata 52W:
$13.88
$33.20
Evommune Inc Stock (EVMN) Company Profile
Nome
Evommune Inc
Settore
Industria
Telefono
(650) 223-7745
Indirizzo
1841 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
24.16 | 851.11M | 13.00M | -68.87M | -76.68M | -2.2276 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-07 | Ripresa | Oppenheimer | Outperform |
| 2026-01-22 | Iniziato | Oppenheimer | Outperform |
| 2026-01-08 | Iniziato | Raymond James | Strong Buy |
| 2026-01-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-12-01 | Iniziato | Evercore ISI | Outperform |
| 2025-12-01 | Iniziato | Leerink Partners | Outperform |
| 2025-12-01 | Iniziato | Morgan Stanley | Overweight |
| 2025-12-01 | Iniziato | William Blair | Outperform |
Mostra tutto
Evommune Inc Borsa (EVMN) Ultime notizie
Certain Rights of Evommune, Inc. are subject to a Lock-Up Agreement Ending on 5-MAY-2026. - marketscreener.com
Wall Street Zen Downgrades Evommune (NYSE:EVMN) to Sell - MarketBeat
Stifel Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Evommune (NYSE:EVMN) Coverage Initiated by Analysts at Stifel Nicolaus - MarketBeat
Stifel initiated coverage on Evommune with a new price target - Quantisnow
Stifel Initiates Evommune(EVMN.US) With Buy Rating, Announces Target Price $54 - Moomoo
Evommune and BillionToOne climb on trading debut - MSN
Evommune surges on mid-stage trial win for eczema therapy - MSN
Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Evommune, Inc.'s (NYSE:EVMN) Lock-Up Period To Expire on May 5th - MarketBeat
[EFFECT] Evommune, Inc. SEC Filing - Stock Titan
Evommune’s EVO756 Phase 2b Trial: An Emerging Catalyst in Atopic Dermatitis - TipRanks
Evommune (NYSE: EVMN) registers 4.49M shares for resale by investors - Stock Titan
EVMN Options Chain — NYSE:EVMN - TradingView
Oppenheimer Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Evommune, Inc. Common Stock (NY: EVMN - FinancialContent
EVMN SEC FilingsEVOMMUNE INC 10-K, 10-Q, 8-K Forms - Stock Titan
Evommune Shelf Registration Raises Dilution Questions After Strong Share Gains - Sahm
EVMN Evommune reports wider Q4 2025 loss than analyst projections, shares dip modestly on soft quarterly earnings.Market Hype Signals - UBND thành phố Hải Phòng
Evommune (EVMN) details 2026 director votes and CEO pay in proxy - Stock Titan
Why is Evommune (EVMN) stock going up today (Institutional Selling) 2026-04-20AI Signals - Cổng thông tin điện tử Tỉnh Sơn La
Evommune (EVMN) Chief Scientific Officer awarded 69,315 stock options at $26.77 - Stock Titan
Evommune (EVMN) grants 73,892 stock options to development chief - Stock Titan
[Form 4] Evommune, Inc. Insider Trading Activity - Stock Titan
Evommune (EVMN) grants CFO 98,946 options at $26.77 strike - Stock Titan
Evommune (EVMN) grants 115,279 stock options to chief legal officer - Stock Titan
Evommune (EVMN) CEO Luis C. Pena receives 291,420 stock option grant - Stock Titan
Evommune Incprospectus filed for resale of up to 4.5 million shares of Evommune common stock by selling stockholdersSEC filing - marketscreener.com
Evommune (NYSE: EVMN) investors file to resell 4.49M previously issued shares - Stock Titan
Evommune stock price target reaffirmed at $50 by H.C. Wainwright - Investing.com South Africa
H.C. Wainwright Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Velan Capital Investment Management LP's Evommune Inc(EVMN) Holding History - GuruFocus
Evommune Makes Case For MRGPRX2 Inhibition in Migraine - Citeline News & Insights
MRGPRX2: A Novel Target in Migraine Treatment – EVO756’s Potential in Migraine Prophylaxis Explained - Minichart
William Blair Maintains Evommune(EVMN.US) With Buy Rating - Moomoo
Evommune: Differentiated MRGPRX2 Strategy and Upcoming EVO756 Phase IIb Readout Support Buy Rating - TipRanks
Evommune Spotlights EVO756 as Novel Preventive Migraine Therapy - TipRanks
Evommune (EVMN) advances oral MRGPRX2 migraine drug EVO756 toward Phase 2b - Stock Titan
RBC Capital Reaffirms Their Buy Rating on Evommune, Inc. (EVMN) - The Globe and Mail
Evommune (NYSE:EVMN) Stock Price Down 7.2%Here's Why - MarketBeat
Evommune's Chronic-Hives Drug May See Wider Use If Trial Succeeds, RBC Says - marketscreener.com
Today's Analyst Rating Update for EVMN: Maintained at Outperform - GuruFocus
Evommune (NYSE:EVMN) Earns Outperform Rating from Royal Bank Of Canada - MarketBeat
RBC Capital Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Evommune (EVMN) Institutional Ownership 2026 - MarketBeat
Evommune (NYSE:EVMN) Advances Within Biotechnology Research And Development - Kalkine Media
Oppenheimer Initiates Evommune(EVMN.US) With Buy Rating, Announces Target Price $50 - Moomoo
Evommune (NYSE:EVMN) Shares Up 4.7%Here's What Happened - MarketBeat
Oppenheimer Initiates Coverage on Evommune (NYSE:EVMN) - MarketBeat
Evommune bucked biotech IPO drought and is focused on the long game - Pharma Voice
Oppenheimer initiates Evommune stock rating at Outperform, $50 target By Investing.com - Investing.com Australia
Evommune Inc Azioni (EVMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):